SOST and cancer: In order to counteract the cancer-induced osteolysis, bone-anabolic agents (e.g., Romosozumab, an antibody against Sclerostin [27]), which are used in clinical practice to treat osteoporosis, are currently emerging as promising treatment approaches [28].